Matt Wolf has been lead trial and appellate counsel in some of the most significant cases brought by and against global life sciences, technology, and consumer goods companies. His professional activities focus on patent, trade secret, licensing, antitrust, and business tort issues.
Matt has been named both a Winning Litigator and Trailblazer by The National Law Journal. He is Chambers (Nationwide) ranked for both IP/Patent Litigation and Intellectual Property, where he has been described as “wickedly smart, very intuitive and terrific in front of a jury” and someone whose “oral advocacy skills are some of the best in the industry.”
He also is top ranked by IAM's Patent Litigation 1000: The World's Leading Patent Litigators, which has noted that he is a "trial supremo;" a "smart guy who knows how to frame the best case," with "tremendous trial skills and a superb ability to think on his feet," and "his cross-examination skills are some of the best." Additionally, he was named a “Client Service All-Star” by BTI Consulting Group. Prior to attending the University of Virginia School of Law, he was World University Debate Champion in 1990.
Experience
- Hologic v. Minerva. As lead trial, appellate, and Supreme Court counsel in patent litigation, secured complete plaintiff and counter-claim defense jury verdict for Hologic, affirmance on appeal, and U.S. Supreme Court upholding of assignor estoppel doctrine. The SCOTUS decision has important implications for patent assignments, employee mobility, and due diligence of corporate transactions.
- Boston Scientific v. Cook Group. Secured a US$158 million jury verdict and a finding of willful infringement as to all asserted patent claims in a suit between competitors in the endoscopy space.
- In re: Mallinckrodt PLC et al. Obtained complete defense verdict in bet-the-company trial, defeating antitrust and civil RICO claims against Mallinckrodt’s leading pharmaceutical, Acthar.
- Amgen v. Sanofi/Regeneron. Successfully invalidated Amgen's patents in jury trial, and subsequently secured affirmance by the Federal Circuit, preserving Sanofi and Regeneron's ability to continue to market its life-saving cholesterol-reducing drug Praluent.
- Hologic v. Fujifilm. Secured a complete win and limited exclusion order in the ITC in investigation of a four patent infringement complaint involving mammography imaging technology.
Perspectives
Recognition
Intellectual Property: Litigation — Washington, D.C. (2011-2024)
Life Sciences: IP/Patent Litigation — Nationwide (2023-2024)
Intellectual Property: Patent — USA (2021-2023)
Credentials
Education
- J.D., University of Virginia School of Law, 1994
- B.A., Political Science, Yale University, 1990
Admissions
- District of Columbia
- Maryland
- U.S. Court of Appeals for the Federal Circuit
- U.S. Court of Appeals for the First Circuit
- U.S. Court of Appeals for the Fourth Circuit
- U.S. District Court, District of Maryland
- U.S. District Court, Eastern District of Texas
- Supreme Court of the United States